Primary Prevention of HPV through Vaccination: Update on the Current Global Status

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Obstetrics and Gynecology Reports

• Publication date

  2016-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13669-016-0165-z
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2016

  2017cited by this paper
• Quadrivalent HPV vaccine effectiveness against high‐grade cervical lesions by age at vaccination: A population‐based study

  2016cited by this paper
• “Saving lives”: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria

  2016cited by this paper
• Prevalence of HPV After Introduction of the Vaccination Program in the United States

  2016cited by this paper
• Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.

  2016cited by this paper
• Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries.

  2016cited by this paper
• Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment

  2016cited by this paper
• Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis

  2016cited by this paper
• Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013

  2016cited by this paper
• Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs.

  2016cited by this paper
• Highest Vaccine Uptake after School-Based Delivery - A County-Level Evaluation of the Implementation Strategies for HPV Catch-Up Vaccination in Sweden

  2016cited by this paper
• Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study

  2016cited by this paper
• Improving Care for Children With ADHD: The Information is Just a Rating Scale Away

  2016cited by this paper
• Argentina's Successful Implementation Of A National Human Papillomavirus Vaccination Program.

  2016cited by this paper
• HPV vaccine introduction in Rwanda: Impacts on the broader health system.

  2016cited by this paper
• HPV vaccine impact in Australian women: ready for an HPV‐based screening program

  2016cited by this paper
• Surveillance of effects of HPV vaccination in Belgium.

  2016cited by this paper
• Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

  2016cited by this paper
• Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada.

  2016cited by this paper
• Trends in Male and Female Genital Warts Among Adolescents in a Safety-Net Health Care System 2004–2013: Correlation With Introduction of Female and Male Human Papillomavirus Vaccination

  2015cited by this paper
• Introduction of a National HPV vaccination program into Bhutan.

  2015cited by this paper
• Measuring HPV vaccination coverage in Australia: comparing two alternative population‐based denominators

  2015cited by this paper
• Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study.

  2015cited by this paper
• Access and Attitudes to HPV Vaccination amongst Hard-To-Reach Populations in Kenya

  2015cited by this paper
• A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

  2015cited by this paper
• Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.

  2015cited by this paper
• Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls.

  2015cited by this paper
• Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine

  2015cited by this paper
• Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

  2015cited by this paper
• The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts

  2015cited by this paper
• Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening

  2015cited by this paper
• Safety of human papillomavirus vaccines: a review

  2015cited by this paper
• HPV Vaccination: Current Global Status

  2015cited by this paper
• Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study

  2015cited by this paper
• Paving pathways: Brazil's implementation of a national human papillomavirus immunization campaign.

  2015cited by this paper
• Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data

  2015cited by this paper
• Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project - Botswana, 2013.

  2015cited by this paper
• Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus.

  2015cited by this paper
• Immunogenicity and safety of the 9-valent HPV vaccine in men.

  2015cited by this paper
• HPV vaccination crisis in Japan.

  2015cited by this paper
• Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.

  2015cited by this paper
• HPV vaccination syndrome. A questionnaire-based study

  2015cited by this paper
• Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review.

  2015cited by this paper
• Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females

  2015cited by this paper
• National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014

  2015cited by this paper
• Immunogenicity and Safety of a 9-Valent HPV Vaccine

  2015cited by this paper
• A cost‐effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer

  2015cited by this paper
• Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine.

  2015cited by this paper
• Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

  2015cited by this paper
• Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.

  2015cited by this paper
• Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

  2014cited by this paper
• Educational interventions to increase HPV vaccination acceptance: a systematic review.

  2014cited by this paper
• Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009–2013

  2014cited by this paper
• Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

  2014cited by this paper
• Corrigendum to: “Human Papillomavirus Vaccine Introduction – The First Five Years” [Vaccine 30 (Suppl. 5) (2012) F139–F148]

  2014cited by this paper
• Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

  2013cited by this paper
• Benefits of catch‐up in vaccination against human papillomavirus in medium‐ and low‐income countries

  2013cited by this paper
• Achieving high coverage in Rwanda's national human papillomavirus vaccination programme.

  2012cited by this paper
• Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

  2012cited by this paper
• Assessment of eight HPV vaccination programs implemented in lowest income countries

  2012cited by this paper
• Complex regional pain syndrome following immunisation

  2012cited by this paper
• Human papillomavirus vaccine introduction--the first five years.

  2012cited by this paper
• Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

  2012cited by this paper
• Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

  2011cited by this paper
• Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

  2011cited by this paper
• Aluminum vaccine adjuvants: are they safe?

  2011cited by this paper
• Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries.

  2011cited by this paper
• Safety and tolerability of bivalent HPV vaccine: An Italian post-licensure study

  2011cited by this paper
• Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.

  2011cited by this paper
• Syncope and seizures following human papillomavirus vaccination: a retrospective case series

  2011cited by this paper
• Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?

  2011cited by this paper
• Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine

  2010cited by this paper
• Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

  2009cited by this paper
• Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

  2009cited by this paper
• Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS

  2009cited by this paper
• Anaphylaxis following quadrivalent human papillomavirus vaccination

  2009cited by this paper
• CNS demyelination and quadrivalent HPV vaccination

  2009cited by this paper
• Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study

  2008cited by this paper
• Mass psychogenic response to human papillomavirus vaccination

  2008cited by this paper
• Human Papilloma Virus Immunization in Adolescent and Young Adults: A Cohort Study to Illustrate What Events Might be Mistaken for Adverse Reactions

  2007cited by this paper
• Causation and causal inference in epidemiology.

  2005cited by this paper
• Risk of anaphylaxis after vaccination of children and adolescents.

  2003cited by this paper
• The Netherlands Source: Cbs/cheps Higher Education Monitor

  year unknowncited by this paper

• A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs

  2024cites this paper
• Racial and ethnic disparities in human papillomavirus (HPV) vaccine uptake among United States adults, aged 27–45 years

  2024cites this paper
• School Nurses’ Experiences and Roles in Promoting and Administering the HPV Vaccine: A Systematic Review Using the Socioecological Framework

  2023cites this paper
• Associations of maternal age, education, and marital status with HPV vaccine uptake and hesitancy among United States Youth: A cross-sectional analysis of the 2020 National Immunization Survey (NIS).

  2023cites this paper
• HPV Vaccination: An Underused Strategy for the Prevention of Cancer

  2022cites this paper
• A Landscape of CRISPR/Cas Technique for Emerging Viral Disease Diagnostics and Therapeutics: Progress and Prospects

  2022cites this paper
• İnsan Papilloma Virüsü (HPV) ve Aşılarının Kullanımı Sonrası Toplumsal Etkileri

  2022cites this paper
• Prevalence of Human Papilloma virus in women with Abnormal Cervical Smears from Sarawak, Malaysia

  2021cites this paper
• The impact of publicly funded immunization programs on human papillomavirus vaccination in boys and girls: An observational study

  2021cites this paper
• Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs

  2021cites this paper
• Cervical Cancer Prevalence in sub-Saharan Africa and HPV Vaccination Policy: A Public Health Grand Challenge?

  2021cites this paper
• Human papillomavirus vaccination and sexual practices among men who have sex with men in Melbourne, Australia: a cross-sectional study

  2020cites this paper
• HPV vaccine and cervical cancer policy and policymaking research interest in sub-Saharan Africa: A scoping review

  2020cites this paper
• Adverse events following HPV vaccination: 11 years of surveillance in Australia.

  2020cites this paper
• HPV vaccine, Twitter, and gay, bisexual and other men who have sex with men.

  2020cites this paper
• Incentivized Screening to Reduce Sexually Transmitted Infection Risk and Prevalence.

  2019cites this paper
• HPV‐vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level

  2019cites this paper
• Japanese physicians’ attitudes and intentions regarding human papillomavirus vaccine compared with other adolescent vaccines

  2019cites this paper
• Health policy and the media: The case of HPV-vaccination

  2019cites this paper
• Political and Public Responses to Human Papillomavirus Vaccination

  2019cites this paper
• Global human papilloma virus vaccine implementation: An update

  2018cites this paper
• Knowledge and beliefs about HPV among college students in Vietnam and the United States.

  2018cites this paper
• The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

  2018cites this paper
• Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies

  2018cites this paper
• Safety of Human Papillomavirus Vaccines: An Updated Review

  2018influential citation
• HPV vaccine implementation and monitoring in Latin America.

  2018cites this paper
• Using an integrated conceptual framework to investigate parents' HPV vaccine decision for their daughters and sons.

  2018cites this paper
• Human Papillomavirus Vaccines: Successes and Future Challenges

  2018cites this paper
• Making HPV vaccination available to girls everywhere

  2018cites this paper
• Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing

  2018cites this paper
• Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage.

  2017cites this paper
• Progress in HPV vaccination in low‐ and lower‐middle‐income countries

  2017cites this paper
• Canadian school-based HPV vaccine programs and policy considerations.

  2017cites this paper
• Confirming cross-protection of bivalent HPV vaccine.

  2017cites this paper
• Parents' involvement in the human papillomavirus vaccination decision for their sons.

  2017cites this paper
• A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada.

  2017cites this paper
• Vaccination to prevent human papillomavirus infections: From promise to practice

  2017cites this paper
• Untangling the psychosocial predictors of HPV vaccination decision-making among parents of boys.

  2017cites this paper